The Asia-Pacific NGS Automation Market is expected to reach $371 million by 2031 at a CAGR of 16.3% from 2024 to 2031. Next-generation Sequencing (NGS) is a genome sequencing technology usually used for research purposes and applied in clinical diagnostics. NGS determines the order of nucleotides in the entire genomes or targeted regions of DNA or RNA. It is used for various clinical applications such as disease diagnosis, prognosis, therapeutic decision, and follow-up of patients. Also, its massive parallel sequencing capacity offers new opportunities for personalized or precision medicine. The automation of library preparation can increase efficiency and generate consistent results. The purpose of bringing automation to NGS is to generate more precise results and increase lab efficiency. NGS automation helps in maintaining turnaround times and expanding sample workload.
The growth of the Asia-Pacific NGS automation market is driven by the growing demand for NGS technology in clinical & research applications, the rising incidence of cancer, and increasing pharmaceutical R&D investments and healthcare expenditures. However, the high costs of automation workstations restrain the market's growth.
The increasing application of NGS in genetic disease testing and government initiatives aimed at boosting the adoption of advanced technologies are expected to create market growth opportunities. However, regulatory & standardization concerns related to diagnostic testing and the need to train personnel on the use of NGS automation software are major challenges for market growth.
Cancer is universally recognized as one of the most complex and costly diseases worldwide. It stands as a prominent cause of death and a significant barrier to improving life expectancy across many nations. The incidence of cancer is on the rise in the Asia-Pacific region. According to Johnson & Johnson (U.S.), Asia-Pacific accounts for approximately 50% of the world’s new cancer cases each year. Mortality due to cancer in the Asia-Pacific is projected to increase by 36% by 2030. Furthermore, the Asia-Pacific region has the highest incidence rates of stomach and liver cancers, with prostate cancer emerging as one of the leading cancers among males in certain Asian countries.
With the rising incidence of cancer, the significance of precision or personalized medicine in oncology has grown substantially, driving the need for researchers to develop effective therapies. Precision medicine plays a crucial role in tailoring treatments for specific tumors, aiding in the determination of more effective tests and treatments. It is often applied to individuals with certain cancers or those at a heightened risk of developing specific cancers. In cancer treatment, precision medicine leverages both the unique genetic makeup of individual patients and genetic information from their tumors to identify and prescribe an appropriate and effective treatment regimen. This trend is expected to drive demand for NGS services, consequently boosting throughput in laboratories.
The increased throughput in labs is expected to boost the demand for automation to increase efficiency and generate consistent and reproducible results. Thus, the rising incidence of cancer and increasing efforts to develop targeted treatment approaches are expected to drive the growth of the NGS automation market during the forecast period.
Click here to: Get Free Sample Pages of this Report
NGS technology has revolutionized the field of genetic disease diagnostics with rapid, high-throughput, and cost-effective approaches. NGS can simultaneously analyze hundreds of genes, the whole exome, and even the whole genome, enabling researchers to gain a deeper understanding of the genetic heterogeneity of rare diseases.
NGS technologies have revolutionized the understanding of unknown species and complex diseases. Recently, the technology has garnered significant attention for diagnosing infectious diseases, immunological disorders, and hereditary conditions. It is also extensively utilized for non-invasive prenatal diagnosis and guiding therapeutic decisions for somatic cancers. The increasing incidence of genetic diseases in the region presents significant market growth opportunities. For instance, according to the Press Information Bureau (India), approximately 10 to 15 thousand newborns are born with Thalassemia in India every year.
NGS holds immense potential to revolutionize cancer diagnosis and care. Leveraging NGS technology enables simultaneous screening of various genomic aberrations, including common and rare variants, structural variations (such as insertions and deletions), copy-number variations, and fusion transcripts. Additionally, Genome-Wide Association Studies (GWAS) facilitate the identification of pathogenically relevant variations and the detection of common variants with minor effects in complex diseases like cancer. The expanding applications of NGS technology are anticipated to offer growth opportunities for players operating in this market.
Based on product, the Asia-Pacific NGS automation market is segmented into workstations/robotic platforms and reagents & consumables. In 2024, the workstations/robotic platforms segment is expected to account for the largest share of the market. The large market share of this segment is attributed to factors such as the high demand for NGS automation among pharmaceutical and biotechnology companies for drug discovery purposes, the increasing utilization of robotic platforms for precise transfer of liquid volumes, coupled with their higher price point, and the enhanced workflow facilitated by minimizing manual interaction with reagents and samples, thereby reducing the risk of contamination.
Based on sequencing type, the Asia-Pacific NGS automation market is segmented into whole genome sequencing, whole exome sequencing, targeted genome sequencing, and other sequencing types. The whole genome sequencing segment is expected to register the highest CAGR during the forecast period. This growth can be attributed to several factors, including the increasing demand for automation in whole genome sequencing to reduce per-sample costs, the expanding applications of whole genome sequencing in identifying inherited disorders and characterizing mutations driving cancer progression, and the tracking of disease outbreaks. Additionally, the rise in whole genome sequencing-based research projects further supports market growth. For instance, in October 2022, BGI Genomics (China), Ruijin Hospital (China), and Shanghai Jiao Tong University Institute of Translational Medicine (China) utilized the DNBSEQ sequencing platform for analyzing non-human genetic sequences in the whole genome sequencing (WGS) data of 10,585 individuals from the China Metabolic Analysis Program (ChinaMAP), thereby constructing the first blood virological profile of the Chinese population.
Based on application, the Asia-Pacific NGS automation market is segmented into drug discovery, clinical diagnostics (oncology, infectious diseases, reproductive health, and other clinical diagnostics), and other applications. In 2024, the drug discovery segment is expected to account for the largest share of the market. NGS plays a crucial role in identifying novel drug targets and developing therapeutic techniques that target specific genes and proteins, including targeted therapies, gene therapies, and oligonucleotide therapies. The growing demand for targeted and gene therapies contributes to the large market share of this segment. Moreover, the gradually increasing number of drug approvals, driven by the need for novel drug therapies, further contributes to the segment’s growth. For instance, according to CDSCO, 27 drugs were approved in India in 2023, compared to 25 drugs approved in 2021.
Based on end user, the Asia-Pacific NGS automation market is segmented into hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, academic & research institutes, and other end users. The hospitals & diagnostic laboratories segment is expected to register the highest CAGR during the forecast period. This growth can be attributed to several factors, including the rising number of hospitalizations for various diseases necessitating diagnosis, the proliferation of hospitals and clinics in the region, and the rising awareness regarding genetic testing, which drives the utilization of diagnostic products.
In 2024, Japan is expected to account for the largest share of the Asia-Pacific NGS automation market. Japan’s major market share can be attributed to several factors, including the country’s high geriatric population, the increasing incidence of cancer, and the significant focus on genomic research. The rising cancer incidence drives the demand for NGS automation products in personalized medicine research. Moreover, various institutions such as the National Cancer Center, universities, and hospitals have initiated NGS-based clinical testing for cancer patients in Japan, further driving the adoption of NGS automation products.
The report offers a competitive landscape based on an extensive assessment of the offerings, geographic presence, and key strategic developments implemented by top market players over the past few years. The key players operating in the Asia-Pacific NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PrimaDiag SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific, Inc. (U.S.), and F. Hoffmann-La Roche Ltd. (Switzerland).
|
Particulars |
Details |
|
Number of Pages |
~200 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
16.3% |
|
Estimated Market Size (Value) |
$371 million by 2031 |
|
Segments Covered |
By Product
By Sequencing Type
By Application
By End User
|
|
Countries Covered |
Japan, China, India, South Korea, Australia, Thailand, Singapore, Indonesia and Rest of Asia-Pacific |
|
Key Companies |
The key players operating in the Asia-Pacific NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PrimaDiag SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific, Inc. (U.S.), and F. Hoffmann-La Roche Ltd. (Switzerland). |
The Asia-Pacific NGS automation market covers the qualitative and quantitative assessment of different products, applications, and end users. This report involves the analysis of various segments of the Asia-Pacific NGS automation market at the regional and country levels.
The Asia-Pacific NGS automation market is projected to reach $371 million by 2031 at a CAGR of 16.3% from 2024 to 2031.
The workstations/robotic platforms segment is estimated to account for the largest share of the Asia-Pacific NGS automation market in 2024. The large market share of this segment is attributed to factors such as the high demand for NGS automation among pharmaceutical and biotechnology companies for drug discovery purposes, the increasing utilization of robotic platforms for precise transfer of liquid volumes, coupled with their higher price point, and the enhanced workflow facilitated by minimizing manual interaction with reagents and samples, thereby reducing the risk of contamination.
Based on application, the drug discovery segment is projected to create more traction during the forecast period due to the increasing use of NGS automation in laboratories to develop therapeutic techniques that target specific genes and proteins, including targeted therapies, gene therapies, and oligonucleotide therapies.
The growth of the Asia-Pacific NGS automation market is driven by the growing demand for NGS technology in clinical & research applications, the rising incidence of cancer, and increasing pharmaceutical R&D investments and healthcare expenditures.
Furthermore, the increasing application of NGS in genetic disease testing and government initiatives aimed at boosting the adoption of advanced technologies are expected to create market growth opportunities.
The key players operating in the Asia-Pacific NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PrimaDiag SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific, Inc. (U.S.), and F. Hoffmann-La Roche Ltd. (Switzerland).
China is expected to offer significant growth opportunities due to the increasing government focus on sequencing projects, the establishment of new healthcare facilities, the large population of patients with gene-associated disorders, and the increasing research activities aimed at developing personalized medicines.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for this Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Growing Demand for NGS Technology in Clinical & Research Applications
4.2.2. Rising Incidence of Cancer
4.2.3. Rising Pharmaceutical R&D Investments & Healthcare Expenditure
4.3. Restraints
4.3.1. High Costs of Automation Workstations
4.4. Opportunities
4.4.1. Government Initiatives to Boost the Adoption of Advanced Technologies
4.4.2. Application of NGS in Genetic Disease Testing
4.5. Challenges
4.5.1. Regulatory & Standardization Concerns Related to Diagnostic Testing
4.6. Trends
4.7. Pricing Analysis
4.8. Regulatory Analysis
4.9. Porter’s Five Force Analysis
4.9.1. Bargaining Power of Buyers
4.9.2. Bargaining Power of Suppliers
4.9.3. Threat of Substitutes
4.9.4. Threat of New Entrant
4.9.5. Degree of Competition
5. Asia-Pacific NGS Automation Market Assessment—by Product
5.1. Overview
5.2. Workstations/Robotic Platforms
5.3. Reagents & Consumables
6. Asia-Pacific NGS Automation Market Assessment—by Technology
6.1. Overview
6.2. Whole Genome Sequencing
6.3. Whole Exome Sequencing
6.4. Targeted Genome Sequencing
6.5. Other Sequencing Types
7. Asia-Pacific NGS Automation Market Assessment—by Application
7.1. Overview
7.2. Drug Discovery
7.3. Clinical Diagnostics
7.3.1. Oncology
7.3.2. Infectious Diseases
7.3.3. Reproductive Health
7.3.4. Other Clinical Diagnostics
7.4. Other Applications
8. Asia-Pacific NGS Automation Market Assessment—by End User
8.1. Overview
8.2. Hospitals & Diagnostic Laboratories
8.3. Pharmaceutical & Biotechnology Companies
8.4. Academics & Research Institutes
8.5. Other End Users
9. Asia-Pacific NGS Automation Market Assessment—by Geography
9.1. Overview
9.2. Japan
9.3. China
9.4. India
9.5. South Korea
9.6. Australia
9.7. Thailand
9.8. Singapore
9.9. Indonesia
9.10. Rest of Asia-Pacific
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis/Market Ranking (2023)
11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1. Agilent Technologies, Inc.
11.2. Danaher Corporation
11.3. Eppendorf AG
11.4. Hamilton Company
11.5. PerkinElmer, Inc.
11.6. Tecan Group Ltd.
11.7. PrimaDiag SAS
11.8. BRAND GMBH + CO KG
11.9. Hudson Robotics
11.10. SPT Labtech
11.11. Thermo Fisher Scientific, Inc.
11.12. F. Hoffmann-La Roche Ltd.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Asia-Pacific NGS Automation Market, by Product, 2022–2031 (USD Million)
Table 2 Asia-Pacific NGS Automation Workstation/Robotics Platform Market, by Country/Region, 2022–2031 (USD Million)
Table 3 Asia-Pacific NGS Automation Reagents & Consumables Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Asia-Pacific NGS Automation Market, by Sequencing Type, 2022–2031 (USD Million)
Table 5 Asia-Pacific NGS Automation Market for Whole Genome Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 6 Asia-Pacific NGS Automation Market for Whole Exome Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 7 Asia-Pacific NGS Automation Market for Targeted Sequencing, by Country/Region, 2022–2031 (USD Million)
Table 8 Asia-Pacific NGS Automation Market for Other Sequencing Types, by Country/Region, 2022–2031 (USD Million)
Table 9 Asia-Pacific NGS Automation Market, by Application, 2022–2031 (USD Million)
Table 10 Asia-Pacific NGS Automation Market for Drug Discovery, by Country/Region, 2022–2031 (USD Million)
Table 11 Asia-Pacific NGS Automation Market for Clinical Diagnostics, by Type, 2022–2031 (USD Million)
Table 12 Asia-Pacific NGS Automation Market for Clinical Diagnostics, by Country/Region, 2022–2031 (USD Million)
Table 13 Asia-Pacific NGS Automation Market for Reproductive Health Diagnostics, by Country/Region, 2022–2031 (USD Million)
Table 14 Asia-Pacific NGS Automation Market for Oncology Diagnostics, by Country/Region, 2022–2031 (USD Million)
Table 15 Asia-Pacific NGS Automation Market for Infectious Disease Diagnostics, by Country/Region, 2022–2031 (USD Million)
Table 16 Asia-Pacific NGS Automation Market for Other Clinical Diagnostics, by Country/Region, 2022–2031 (USD Million)
Table 17 Asia-Pacific NGS Automation Market, by End User, 2022–2031 (USD Million)
Table 18 Asia-Pacific NGS Automation Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 19 Asia-Pacific NGS Automation Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 20 Asia-Pacific NGS Automation Market for Academic & Research Institutes, by Country/Region, 2022–2031 (USD Million)
Table 21 Asia-Pacific NGS Automation Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 22 Asia-Pacific NGS Automation Market, by Country/Region, 2022–2031 (USD Million)
Table 23 Japan: NGS Automation Market, by Product, 2022–2031 (USD Million)
Table 24 Japan: NGS Automation Market, by Sequencing Type, 2022–2031 (USD Million)
Table 25 Japan: NGS Automation Market, by Application, 2022–2031 (USD Million)
Table 26 Japan: NGS Automation Market for Clinical Diagnostics, by Type, 2022–2031 (USD Million)
Table 27 Japan: NGS Automation Market, by End User, 2022–2031 (USD Million)
Table 28 China: NGS Automation Market, by Product, 2022–2031 (USD Million)
Table 29 China: NGS Automation Market, by Sequencing Type, 2022–2031 (USD Million)
Table 30 China: NGS Automation Market, by Application, 2022–2031 (USD Million)
Table 31 China: NGS Automation Market for Clinical Diagnostics, by Type, 2022–2031 (USD Million)
Table 32 China: NGS Automation Market, by End User, 2022–2031 (USD Million)
Table 33 India: NGS Automation Market, by Product, 2022–2031 (USD Million)
Table 34 India: NGS Automation Market, by Sequencing Type, 2022–2031 (USD Million)
Table 35 India: NGS Automation Market, by Application, 2022–2031 (USD Million)
Table 36 India: NGS Automation Market for Clinical Diagnostics, by Type, 2022–2031 (USD Million)
Table 37 India: NGS Automation Market, by End User, 2022–2031 (USD Million)
Table 38 South Korea: NGS Automation Market, by Product, 2022–2031 (USD Million)
Table 39 South Korea: NGS Automation Market, by Sequencing Type, 2022–2031 (USD Million)
Table 40 South Korea: NGS Automation Market, by Application, 2022–2031 (USD Million)
Table 41 South Korea: NGS Automation Market for Clinical Diagnostics, by Type, 2022–2031 (USD Million)
Table 42 South Korea: NGS Automation Market, by End User, 2022–2031 (USD Million)
Table 43 Australia: NGS Automation Market, by Product, 2022–2031 (USD Million)
Table 44 Australia: NGS Automation Market, by Sequencing Type, 2022–2031 (USD Million)
Table 45 Australia: NGS Automation Market, by Application, 2022–2031 (USD Million)
Table 46 Australia: NGS Automation Market for Clinical Diagnostics, by Type, 2022–2031 (USD Million)
Table 47 Australia: NGS Automation Market, by End User, 2022–2031 (USD Million)
Table 48 Thailand: NGS Automation Market, by Product, 2022–2031 (USD Million)
Table 49 Thailand: NGS Automation Market, by Sequencing Type, 2022–2031 (USD Million)
Table 50 Thailand: NGS Automation Market, by Application, 2022–2031 (USD Million)
Table 51 Thailand: NGS Automation Market for Clinical Diagnostics, by Type, 2022–2031 (USD Million)
Table 52 Thailand: NGS Automation Market, by End User, 2022–2031 (USD Million)
Table 53 Singapore: NGS Automation Market, by Product, 2022–2031 (USD Million)
Table 54 Singapore: NGS Automation Market, by Sequencing Type, 2022–2031 (USD Million)
Table 55 Singapore: NGS Automation Market, by Application, 2022–2031 (USD Million)
Table 56 Singapore: NGS Automation Market for Clinical Diagnostics, by Type, 2022–2031 (USD Million)
Table 57 Singapore: NGS Automation Market, by End User, 2022–2031 (USD Million)
Table 58 Indonesia: NGS Automation Market, by Product, 2022–2031 (USD Million)
Table 59 Indonesia: NGS Automation Market, by Sequencing Type, 2022–2031 (USD Million)
Table 60 Indonesia: NGS Automation Market, by Application, 2022–2031 (USD Million)
Table 61 Indonesia: NGS Automation Market for Clinical Diagnostics, by Type, 2022–2031 (USD Million)
Table 62 Indonesia: NGS Automation Market, by End User, 2022–2031 (USD Million)
Table 63 Rest of Asia-Pacific: NGS Automation Market, by Product, 2022–2031 (USD Million)
Table 64 Rest of Asia-Pacific: NGS Automation Market, by Sequencing Type, 2022–2031 (USD Million)
Table 65 Rest of Asia-Pacific: NGS Automation Market, by Application, 2022–2031 (USD Million)
Table 66 Rest of Asia-Pacific: NGS Automation Market for Clinical Diagnostics, by Type, 2022–2031 (USD Million)
Table 67 Rest of Asia-Pacific: NGS Automation Market, by End User, 2022–2031 (USD Million)
Table 68 Recent Developments, by Company (2020-2024)
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Asia-Pacific NGS Automation Market, by Product, 2024 VS. 2031 (USD Million)
Figure 8 Asia-Pacific NGS Automation Market, by Sequencing Type, 2024 VS. 2031 (USD Million)
Figure 9 Asia-Pacific NGS Automation Market, by Application, 2024 VS. 2031 (USD Million)
Figure 10 Asia-Pacific NGS Automation Market, by End User, 2024 VS. 2031 (USD Million)
Figure 11 Factors Affecting Market Growth
Figure 12 Asia-Pacific NGS Automation Market, by Product, 2024 VS. 2031 (USD Million)
Figure 13 Asia-Pacific NGS Automation Market, by Sequencing Type, 2024 VS. 2031 (USD Million)
Figure 14 Asia-Pacific NGS Automation Market, by Application, 2024 VS. 2031 (USD Million)
Figure 15 Asia-Pacific NGS Automation Market, by End User, 2024 VS. 2031 (USD Million)
Figure 16 Asia-Pacific NGS Automation Market, by Country/Region, 2024 VS. 2031 (USD Million)
Figure 17 Asia-Pacific: NGS Automation Market Snapshot
Figure 18 Key Growth Strategies Adopted by Leading Players, 2020—2024
Figure 19 Asia-Pacific NGS Automation Market: Competitive Benchmarking, by Product
Figure 20 Asia-Pacific NGS Automation Market: Competitive Dashboard
Figure 21 Asia-Pacific NGS Automation Market: Market Share Analysis (2023)
Figure 22 Agilent Technologies, Inc.: Financial Snapshot (2023)
Figure 23 Danaher Corporation: Financial Snapshot (2022)
Figure 24 Eppendorf AG: Financial Snapshot (2022)
Figure 25 PerkinElmer, Inc.: Financial Snapshot (2022)
Figure 26 Tecan Group Ltd.: Financial Snapshot (2022)
Figure 27 Thermo Fisher Scientific, Inc.: Financial Snapshot (2022)
Figure 28 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Dec-2023
Published Date: Nov-2023
Published Date: Oct-2023
Published Date: Sep-2023
